FIELD: chemistry; medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to chemistry, medicine and pharmaceutics, namely to an injection solution for boron-neutron capture therapy by intravenous drop injection and to a method of boron-neutron capture therapy. Proposed injection solution contains: 2.0–5.5 wt./vol.% of p-boronophenylalanine (or a pharmaceutically acceptable salt thereof) with a proportion of boron atoms-10 of boron atoms in compound of 75% or more; 2.0–7.0 wt./vol.% of sugar alcohol selected from sorbitol or mannitol; 0.01–0.6 wt./vol.% of antioxidant selected from sodium pyrosulphite, sodium sulphite or sodium bisulphite; citric acid for pH adjustment; water, wherein molar ratio of sugar alcohol and p-boronophenylalanine is (0.9–3.0):1.
EFFECT: group of inventions provides an injection solution effective for tumour reduction during boron-neutron capture therapy, which is stable both at low (5 °C ± 3 °C) and higher (40 °C) temperature.
4 cl, 1 dwg, 4 tbl, 72 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PREVENTING PRECIPITATION IN INJECTION SOLUTION CONTAINING P-BORONOPHENYLALANINE | 2020 |
|
RU2833356C1 |
BORYLATED AMINO ACID COMPOSITIONS FOR USE IN BORON NEUTRON CAPTURE THERAPY AND METHODS THEREOF | 2020 |
|
RU2818817C2 |
METHOD FOR PRODUCING L-BPA | 2016 |
|
RU2688676C1 |
PAIR-BORPHENYLALANINE DERIVATIVE AND A COMPOSITION CONTAINING THESE, AND A KIT FOR OBTAINING THE MENTIONED DERIVATIVE AND COMPOSITION | 2019 |
|
RU2797343C2 |
NIDO-CARBORAN-CONTAINING FOLIC ACID BIS-AMIDES FOR BORON DELIVERY TO TUMOR CELLS | 2022 |
|
RU2794768C1 |
BORON COMPOUNDS EFFECTIVE IN BORON NEUTRON CAPTURE THERAPY | 2006 |
|
RU2423368C2 |
BORON-CONTAINING COMPOUND | 2017 |
|
RU2739198C2 |
METHOD OF PRODUCING A COMPOSITION FOR BORON-NEUTRON CAPTURE THERAPY OF MALIGNANT TUMORS (VERSIONS) | 2019 |
|
RU2720458C1 |
THIENO[3,2-d]PYRIMIDINE DERIVATIVE AS PHOSPHATIDYL INOSITOL-3-KINASE (PI3K) INHIBITOR | 2007 |
|
RU2439074C2 |
LIPOSOMAL COMPOSITION | 2010 |
|
RU2476216C1 |
Authors
Dates
2024-12-23—Published
2020-09-09—Filed